LQDA vs TENX
LQDA: Liquidia is a rare-disease biopharmaceutical company commercializing YUTREPIA, a next-generation inhaled treprostinil with proprietary particle engineering, for pulmonary hypertension. TENX: Tenax Therapeutics is a clinical-stage biotechnology company developing specialized therapies for pulmonary hypertension and other cardiopulmonary conditions.
Side-by-side fundamentals
| Metric | LQDA | TENX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $84.11 | $16.19 | |
| Market cap as of 2026-08-03 | $7.5B | $429M | |
| P/E as of 2026-08-03 | 335.34 | n/a | |
| Net margin as of 2026-08-03 | +7.7% | -10115.8% | LQDA higher |
| Gross margin as of 2026-08-03 | +91.8% | +100.0% | TENX higher |
| Operating margin as of 2026-08-03 | +15.8% | -10390.5% | LQDA higher |
| ROE as of 2026-08-03 | +46.8% | -56.3% | LQDA higher |
| ROA as of 2026-08-03 | +7.1% | -53.1% | LQDA higher |
| Debt / equity as of 2026-08-03 | 1.64 | 0.00 | TENX lower |
| Revenue growth (YoY) as of 2026-08-03 | +1936.7% | -82.9% | LQDA higher |
| Revenue CAGR (3y) SEC XBRL | +115.0% | n/a | |
| Beta as of 2026-08-03 | 1.08 | 0.96 | |
| 1-year return as of 2026-07-31 close | +350.0% | +167.6% | LQDA higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.